Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

Summary

The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.

In the site led by Dr. Altice, we compare two models of providing HIV care and buprenorphine treatment. Assignments are based on participants' city of residence. In the onsite (integrated care) model, participants receive buprenorphine, substance abuse counseling and HIV care at one location: the Waterbury Hospital Infectious Disease Clinic. In the off-site model (non-integrated care) buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively. Data is collected from interviews with participants, reviews of medical records, and surveys and interviews with clinicians.

Conditions

• Buprenorphine
• HIV
• Drug Abuse
• Drug Addiction
• Drug Dependence
• Drug Use Disorders
• Drug Use Disorder
• Substance Abuse
• Opiate Addiction
• Substance-related Disorders

Interventions

OTHER

Services will be provided at one site

Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..

OTHER

Services remain dispersed; i.e., not centralized to one-location or provider.

Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.

Sponsors & Collaborators

• Waterbury Hospital

  collaborator UNKNOWN

• Health Resources and Services Administration (HRSA)

  collaborator FED

• The New York Academy of Medicine

  collaborator OTHER

• Yale University

  lead OTHER

Principal Investigators

• Frederick Altice, MD · Yale University

Study Design

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-08-31

Primary Completion

2010-08-31

Completion

2010-08-31

Countries

• United States

Study Locations